Regeneron Pharmaceuticals, Inc. (REGN) earnings on July 30, 2026

Before the market opens Q2 2026

More Regeneron Pharmaceuticals, Inc. earnings

Prior outlook: Optimistic Outcome: Accurate

Regeneron Pharmaceuticals beat earnings and sales estimates despite a partner dropping a drug candidate. The stock rose over 6%.

REGN price around the earnings

738.34

Change: +6.2%

2026-07-30, 20:00 UTC

Start of the measured window End of the measured window
682.00 701.31 720.62 739.93 695.42
Price series around the eventClosing price per minute from before the event to the end of the measured window.
July 30, 2026
  • Price: green if it ends above the starting price; red if it ends below
  • Start of the measured window
  • End of the measured window
  • Market open
  • Starting price
Price series around the event

Prior thesis

Prior outlook: Optimistic Outcome: Accurate

Thesis published
Results released

Exceptional historical beats and strong analyst upside, with positive trend strength, but drug candidate news adds uncertainty.

Context analyzed before publication

Trend
Strong and accelerating run-up into earnings, indicating high expectations and potential for sell-the-news.

Analysts

Evidence

Analyst consensus
Buy
Consensus average (1-5)
1.81
Analysts covering the stock
26
Average price target
819.25
Lowest price target
641
Highest price target
1,000
Upside to price target
17.8%
Quarterly earnings growth
-10.1%
Revenue growth
19%
Forward EPS
54.61
Trailing EPS
40.96
Analyst moves in the last 60 days
8
  • Strong buy: 4
  • Buy: 14
  • Hold: 9
  • Sell: 0
  • Strong sell: 0
Strong buy
4
Buy
14
Hold
9
Sell
0
Strong sell
0
  • July 21, 2026 · Guggenheim: Maintains rating (Buy → Buy)
  • July 9, 2026 · Piper Sandler: Maintains rating (Overweight → Overweight)
  • July 8, 2026 · Morgan Stanley: Maintains rating (Equal-Weight → Equal-Weight)
  • July 7, 2026 · RBC Capital: Maintains rating (Sector Perform → Sector Perform)
  • July 7, 2026 · Truist Securities: Maintains rating (Buy → Buy)
  • July 7, 2026 · Benchmark: Upgrades rating (Hold → Buy)
  • July 6, 2026 · HSBC: Maintains rating (Buy → Buy)
  • July 6, 2026 · Cantor Fitzgerald: Maintains rating (Overweight → Overweight)

News and sentiment

Evidence

Sentiment
Sentiment
Constructive
Mention volume
Low
Normalized volume
33%
News
Sources (7)

Technicals

Evidence

Price when the context was analyzed
696.55
Average true range (ATR)
2.5%
Distance to 52-week high
-14.2%
14-day change (14d)
+4.8%
30-day change (30d)
+10.2%
30-day relative strength
+18.8%
QQQ change (30d)
-8.6%
Nearest support
693.2
Distance to nearest support
0.5%
Nearest resistance
701.25
Distance to nearest resistance
0.7%
Volume accumulation ratio (14d / 46d)
0.78
  • Major: 693.2 (0.5% away, 0.19 ATR, 29 touches)
  • Major: 685.77 (1.6% away, 0.63 ATR, 27 touches)
  • Mid: 681.35 (2.2% away, 0.89 ATR, 18 touches)
  • Major: 701.25 (0.7% away, 0.28 ATR, 39 touches)
  • Major: 709.33 (1.8% away, 0.74 ATR, 24 touches)
  • Major: 716.91 (2.9% away, 1.19 ATR, 29 touches)

Trends

Evidence

Average earnings surprise
+22.0%
  • April 29, 2026: actual EPS 9.47 vs estimate 8.9 (surprise +6.4%)
  • January 30, 2026: actual EPS 11.44 vs estimate 10.75 (surprise +6.4%)
  • October 28, 2025: actual EPS 11.83 vs estimate 9.64 (surprise +22.7%)
  • August 1, 2025: actual EPS 12.89 vs estimate 8.44 (surprise +52.7%)

Expected move

Implied move
+7.8%
Source
Options chain

Reactions over its last 20 earnings

Median move
3.8%
75th percentile move
6.1%
90th percentile move
7.2%
Up / down moves
12 / 8
Average up move
+4.0%
Average down move
-4.0%

Monitoring and close

What Regeneron Pharmaceuticals, Inc. reported

Status
Finished
Actual EPS14.29
EPS estimate10.26
EPS surprise+39.3%
Revenue$4,291 million
Revenue estimate$3,816 million
Revenue surprise+12.4%

Regeneron beat Q2 estimates with $4.3B revenue on strong Dupixent and Eylea HD demand. Healthcare stocks declined Thursday, with the NYSE Healthcare Index down 1.5%.

Sources (16)

Pre-market second reading after the results

Verdict
Beat expectations

Heading into the open, results beat expectations on both earnings and revenue and the price is indicating +3.4% pre-market, a move in line with the stock's usual reaction (about 4%). The figures confirm the optimistic scenario. Across our market history, in the 1,267 similar cases the close held that direction 86% of the time.

How the stock reacted

Outcome
Accurate
Consolidated
+6.2%
Max favorable move (MFE)
6.4%
Max adverse move (MAE)
1.4%